Christopher Durant Turner - Jan 4, 2022 Form 4 Insider Report for Nuvalent, Inc. (NUVL)

Role
Chief Medical Officer
Signature
/s/ Alexandra Balcom, attorney-in-fact
Stock symbol
NUVL
Transactions as of
Jan 4, 2022
Transactions value $
$0
Form type
4
Date filed
1/5/2022, 04:26 PM
Previous filing
Jul 28, 2021
Next filing
May 19, 2022

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NUVL Stock Option (Right to Buy) Award $0 +107K $0.00 107K Jan 4, 2022 Common Stock 107K $18.93 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares underlying this option vest as follows: 25% of the shares vest on January 4, 2023, and the remainder vest over the next three years in equal monthly installments, subject to continued service to Nuvalent, Inc. through the applicable vesting date.